Stock Analysis of Cingulate Inc (CING) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code CING
Close 0.802
Change 0.0119 / 1.51 %
Volume 16874.00
Vol Change -39446.00 / 70.04 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Very Low Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Cingulate Inc
PE (TTM)

-0.0315

Very Poor
Price / Book

-0.319

Very Poor
Price / Sales

-0.103

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

4848.67 K

Enterprise Value

8171.40 K

ROA (TTM)

-261.09

Very Poor
ROE (TTM)

0

Poor
Net Margin (TTM)

327.33

Excellent
Revenue

%

0
Net Profit

19.97 %

-21205.28 K
Debt to Equity

-0.491

Very Poor
Altman Z Score

-0.0210

Very Poor
Quick Ratio

0

Poor
Cash Ratio

0.0051

Poor


Highs/Lows of Cingulate Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.761 5.37 % 1.54 % 0.85490.75116-May-2414-May-24
Two Week0.9646 16.87 % 3.42 % 1.03990.706-May-2410-May-24
One Month0.8518 5.86 % 5.60 % 1.160.702-May-2410-May-24
Three Month1.16 30.87 % 5.95 % 1.50.701-Mar-2410-May-24
Six Months6.002 86.64 % 17.48 % 12.70.728-Dec-2310-May-24
One year19.0 95.78 % 27.52 % 21.60.702-Jun-2310-May-24
Two year24.8 96.77 % 29.70 % 38.60.724-Feb-2310-May-24


Technical View of Cingulate Inc
RSI

39.94

Neutral
MACD

-0.062

Mild Bearish
ADX

14.23

Bearish
Super Trend

1.06

Strong Bearish
Williams %R

-77.85

Mild Bullish
CCI

-106.74

Mild Bullish


EMA 5

0.805

Mild Bearish
EMA 15

0.851

Mild Bearish
EMA 50

1.18

Mild Bearish
EMA 100

2.48

Mild Bearish
SMA 100

2.18

Mild Bearish
SMA 200

5.88

Mild Bearish
SMA 5 / 20

0.797 / 0.877

Strong Bearish
SMA 15 / 50

0.879 / 0.983

Mild Bearish
SMA 50 / 200

0.983 / 5.88

Strong Bearish




Charts of Cingulate Inc


Returns of Cingulate Inc with Peers
Period / StockCINGBVXVDRUGENSC
1 Week5.37%1.49%3.76%19.08%
1 Mth-5.86%-1.45%-3.51%-0.921%
3 Mth-30.87%-5.00%-43.59%-32.84%
6mth-86.64%-40.09%-13.13%-31.05%
1 Year-95.78%-86.74%-60.51%-78.48%
2 Year-96.77%-94.47%-78.43%-99.56%
5 Years--97.58%--99.97%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Cingulate Inc with Peers
Ratio / StockCINGBVXVDRUGENSC
PE-0.0315140.98-0.495-0.180
P/B-0.3191099.290.4131.37
ROA-261.0910.63-76.79-271.39
ROE0779.74-83.45-650.98
Debt To Equity-0.491-11.630.0111-1.31
Revenue0
% 		0
100.00 % 		0
% 		2230.52 K
11.61 %
Net Income-21205.28 K
19.97 % 		-5796.00 K
85.50 % 		-7372.23 K
50.74 % 		-12599.98 K
49.77 %


Technicals of Cingulate Inc with Peers
Technical / StockCINGBVXVDRUGENSC-
ADX14.2321.2424.3029.44
CMF-0.0308-0.078-0.1380.119
MFI51.1467.9140.2962.93
RSI39.9452.5247.7250.76
MACD Abv SignalFalseTrueTrueTrue
Price Above 50 MAFalseFalseFalseFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : Cingulate Inc

Address : 1901 West 47th Place, Kansas City, KS, United States, 66205
Tel : 913 942 2300
URL : https://www.cingulate.com
Code : CING, ISIN : US17248W1053, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 08_Dec_2021
Employee Count : 13

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.


Note : All Data Generated at the End of Trading Hours (EOD Data)